327 reports of this reaction
2.1% of all ENTECAVIR reports
#8 most reported adverse reaction
HEPATITIS B is the #8 most commonly reported adverse reaction for ENTECAVIR, manufactured by E.R. Squibb & Sons, L.L.C.. There are 327 FDA adverse event reports linking ENTECAVIR to HEPATITIS B. This represents approximately 2.1% of all 15,216 adverse event reports for this drug.
Patients taking ENTECAVIR who experience hepatitis b should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATITIS B is a less commonly reported adverse event for ENTECAVIR, but still significant enough to appear in the safety profile.
In addition to hepatitis b, the following adverse reactions have been reported for ENTECAVIR:
The following drugs have also been linked to hepatitis b in FDA adverse event reports:
HEPATITIS B has been reported as an adverse event in 327 FDA reports for ENTECAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATITIS B accounts for approximately 2.1% of all adverse event reports for ENTECAVIR, making it a notable side effect.
If you experience hepatitis b while taking ENTECAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.